The myPKFiT software is intended for use by licensed healthcare professionals (HCPs) who are familiar with hemophilia care. The myPKFiT software can be used to generate ADVATE dosage amount and frequency recommendations for routine prophylaxis for an individual patient 16 years of age and older and body ...
Learn about AFSTYLA, recombinant FVIII therapy that delivers long-lasting bleed protection for patients with hemophilia A. Explore how to sign up your patients for a free 30-day trial.
Information for healthcare providers about ELOCTATE® [Antihemophilic factor (recombinant), Fc fusion protein].
The official HCP site for FEIBA. Please see Detailed Important Risk Information including BOXED WARNING and full Prescribing Information.
IXINITY® is a recombinant factor IX hemophilia B treatment option. Healthcare professionals, get IXINITY savings, dosage, and clinical information.
Official site from Bayer. Learn about Kogenate® FS, Antihemophilic Factor (Recombinant), including uses, safety and administration information.
KOVALTRY®, Antihemophilic Factor (Recombinant), is the only unmodified, full-length rFVIII. Please see full Important Safety Information.
HCP site for Rebinyn® Coagulation Factor IX (Recombinant), GlycoPEGylated, a treatment for hemophilia from Novo Nordisk. Read Important Safety ...
Learn more about OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence], a recombinant porcine sequence factor.
IDELVION is the only treatment for hemophilia B with 14 - day dosing. With 7- and 14- day dosing regimens, give your patients greater freedom from infusions.
Jivi® has received FDA approval and is now available
Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, among other indications. See Prescribing Info.
Use our convenient dosing calculator. With our dosing calculator, you can quickly determine the recommended NovoSeven® RT dose for your patient, plus the number of vials required.
FVIII/VWF complex. ... ALPHANATE is the only FVIII/VWF complex to offer the convenience of a large 2000-IU vial size with low diluent volume. ... The ALPHANATE manufacturing process includes 10 steps to safety, with full traceability from donor to patient.
Find more information, including benefits and risks about Pfizer Hemophilia's factor IX therapy for your hemophilia B patients.
Allergic-type hypersensitivity reactions, including anaphylaxis, are possible with XYNTHA®. Inform patients of the early signs or symptoms of hypersensitivity reactions (including hives, generalized urticaria, chest tightness, wheezing, and hypotension) and anaphylaxis.
HEMOFIL M is indicated in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes.
The use of RECOMBINATE [Antihemophilic Factor (Recombinant)] is indicated in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes.2 RECOMBINATE is also indicated in the perioperative management of patients with hemophilia A (classical hemophilia).